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Reduced expression of the survival motor neuron (SMN) gene causes the childhood motor neuron disease
spinal muscular atrophy (SMA). Low levels of ubiquitously expressed SMN protein result in the degeneration
of lower motor neurons, but it remains unclear whether other regions of the nervous system are also affected.
Here we show that reduced levels of SMN lead to impaired perinatal brain development in a mouse model of
severe SMA. Regionally selective changes in brain morphology were apparent in areas normally associated
with higher SMN levels in the healthy postnatal brain, including the hippocampus, and were associated with
decreased cell density, reduced cell proliferation and impaired hippocampal neurogenesis. A comparative
proteomics analysis of the hippocampus from SMA and wild-type littermate mice revealed widespread modi-
fications in expression levels of proteins regulating cellular proliferation, migration and development when
SMN levels were reduced. This study reveals novel roles for SMN protein in brain development and mainten-
ance and provides the first insights into cellular and molecular pathways disrupted in the brain in a severe
form of SMA.
INTRODUCTION
Proximal spinal muscular atrophy (SMA), a leading genetic
cause of infant mortality, is an autosomal-recessive neuromus-
cular disorder with a carrier frequency of 1:50 and an annual
incidence of around 1:10 000 live births (1). SMA is classi-
cally characterized by degeneration and loss of large alpha
motor neurons in the ventral horn of the spinal cord and
paralysis of proximal muscles in the limbs and trunk, resulting
from denervation at the neuromuscular junction (2–5). The
most severe and common form of SMA, accounting for
50% of SMA diagnoses (SMA type I; Werdnig–Hoffmann
syndrome), leads to disease onset in the first 6 months of
life, no achievement of sitting without support and death
within the first 2 years of life (5,6).
The vast majority of SMA cases are caused by homozygous
deletion of the survival motor neuron 1 (SMN1) gene, leading
to reduced expression levels of full-length SMN protein (7).
SMN protein is known to play a critical role in several
core cellular pathways, including snRNP biogenesis and
pre-mRNA splicing (reviewed in 8,9). Previous studies have
suggested that motor neuron-specific changes in splicing path-
ways may be responsible for tissue-specific targeting in SMA
(10), although recent evidence has shown that these changes
are likely to occur as a consequence, rather than a cause, of
the disease (11).
Although SMN protein is ubiquitously expressed in tissues
and organs across a range of different species, including rats,
monkeys and humans (12), the extent to which SMN
deficiency leads specifically to targeted pathological changes
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in the neuromuscular system remains unclear. For example,
the fact that significant levels of SMN protein have previously
been identified in the brain (12,13) raises the possibility that
reduced levels of expression may have effects on non-motor
regions of the nervous system. Here, we show that reduced
levels of SMN protein result in regionally selective, impaired
brain development in a mouse model of severe SMA
[Smn2/2;SMN2 mice (14)]. In highly affected regions,
such as the hippocampus, SMN deficiency resulted in lower
cell density, decreased cell proliferation and decreased post-
natal neurogenesis. Proteomic analysis of the hippocampus
from SMA mice revealed changes in molecular pathways
involved in cellular proliferation, migration and development.
RESULTS
Regionally specific modifications in brain morphology
reveal abnormal postnatal brain development in a mouse
model of severe SMA
To establish whether reduced levels of SMN protein influence
brain morphology, we examined postnatal brain development
in an established mouse model of severe SMA
[Smn2/2;SMN2 mice (14)]. A comparison of whole, freshly
dissected brains from Smn2/2;SMN2 mice with brains from
non-affected, wild-type littermates (Smn+/+;SMN2 mice) at
a late-symptomatic disease time point (postnatal Day 5; P5)
revealed a significant reduction in brain size and weight
(Fig. 1C and D). Equivalent analysis at a pre-symptomatic
time point (P1) revealed that brains from Smn2/2;SMN2
mice were indistinguishable from those of control littermates
and were of an almost identical weight (Fig. 1A and B). Thus,
gross morphological changes were apparent in the brains of
mice with a severe form of SMA at late-symptomatic ages.
Higher-resolution morphological assessment of Nissl-
stained coronal brain sections from Smn2/2;SMN2 mice at
pre- and late-symptomatic time points revealed region-specific
effects of reduced SMN levels. Qualitatively, the most striking
morphological changes were observed in the hippocampus and
particularly the hippocampal dentate gyrus. This region was
noticeably smaller in Smn2/2;SMN2 mice at late-
symptomatic time points (Fig. 2). Quantitative assessment
confirmed our qualitative observations, as by P6 the area of
the hippocampal dentate gyrus was 50% smaller in
Smn2/2;SMN2 mice compared with wild-type littermates
(Fig. 2E). Statistical comparisons of hippocampal dentate
gyrus area in Smn2/2;SMN2 and littermate control mice con-
firmed a significant effect of the reduction in SMN levels
[two-way ANOVA; P , 0.001; F(1,35) ¼ 20.45]. Interest-
ingly, previous reports have cited the hippocampus as a
brain region likely to be particularly susceptible to SMA path-
ology in human patients with severe forms of SMA (15).
More modest morphological reductions were observed in
the primary motor cortex (M1) of Smn2/2;SMN2 mice.
These subtle morphological differences were present at the
time of birth (pre-symptomatically) and persisted through late-
symptomatic stages where they became statistically significant
(Fig. 2A and B). Despite this decrease in motor cortex thick-
ness, the primary somatosensory cortex (S1BF) remained
unaffected in Smn2/2;SMN2 mice at all stages of disease
progression [Fig. 3; two-way ANOVA; P. 0.05; F(1,36) ¼
3.93], suggesting that distinct cortical areas were differentially
affected. Importantly, the finding that not all brain regions
were equally affected in Smn2/2;SMN2 mice confirmed
that the developmental changes identified were likely to rep-
resent specific vulnerability of regions such as the hippo-
campus, rather than simply occurring as a result of
generalized shrinkage caused by the reduced body size of late-
symptomatic Smn2/2;SMN2 mice (14).
These data suggest that perinatal growth and development
of a subset of brain regions are disrupted when SMN levels
are reduced to those known to cause a severe form of SMA
in mice, with disruption of the hippocampal formation being
particularly apparent.
Reduced density and proliferation of cells in the
hippocampi of mice with severe SMA
Next, we asked whether changes in cell density and/or pro-
liferation could account for the morphological changes
observed in the brains of Smn2/2;SMN2 mice. We decided
to focus on the hippocampus for these experiments, as this
region showed the most dramatic morphological changes
(see above). Smn2/2;SMN2 mice had significantly fewer
cell nuclei in the hippocampal dentate gyrus at late-
symptomatic time points compared with wild-type littermate
mice (Fig. 4A and B; P , 0.01, unpaired t-test).
This reduced cell density correlated with a significant
Figure 1. Modified brain size and weight in mice with severe SMA. (A) Photo-
graph showing two representative brains, one from an Smn2/2;SMN2 mouse
(right) and the other from a wild-type littermate mouse (left) at a pre-
symptomatic time point (postnatal Day 1; P1). There were no observable differ-
ences in the gross appearance or size of the brain between genotypes at this age.
(B) Bar chart (mean+SEM) showing mean brain weights from
Smn2/2;SMN2 (2/2) and wild-type littermate (+/+) mice at P1 (+/+
n ¼ 4 mice; 2/2 n ¼ 3). There was no significant difference between the
two genotypes (P. 0.05, unpaired t-test). (C) Photograph showing two repre-
sentative brains, one from an Smn2/2;SMN2 mouse (right) and the other from
a wild-type littermate mouse (left) at a late-symptomatic time point (P5). At this
age, brains from Smn2/2;SMN2 mice were noticeably smaller than those from
wild-type mice. (D) Bar chart showing mean brain weights from
Smn2/2;SMN2 and wild-type littermate mice at P5 (n ¼ 6 per genotype).
There was a significant reduction in brain weight in the Smn2/2;SMN2 mice
(∗∗P , 0.01; unpaired t-test). Scale bar ¼ 0.75 cm (A), 1 cm (C).
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reduction in the numbers of proliferating cells in the hippo-
campus in Smn2/2;SMN2 mice, identified using Ki67 as an
immunocytochemical marker of proliferation (Fig. 4C and
D; P , 0.001, unpaired t-test). These experiments suggested
that attenuated cell proliferation was leading to reduced
numbers of cells in the hippocampus. A comparison of cell
densities in two unaffected brain regions—the primary soma-
tosensory cortex and ventral thalamic nuclei (VPM/VPL
Figure 2. Modified morphological development of the hippocampus and primary motor cortex in severe SMA mice. (A) Primary motor cortex (M1; white line)
in Nissl-stained brain sections from wild-type (WT) and Smn2/2;SMN2 (SMA) mice at pre-symptomatic (P1) and late-symptomatic (P6) ages. Modest
reductions were apparent in M1 thickness of Smn2/2;SMN2 mice at both pre- and late-symptomatic ages. (B) Bar chart (mean+SEM) showing M1 thickness
in wild-type (+/+) and Smn2/2;SMN2 (2/2) mice at P1, P3 and P6. There were modest reductions in M1 thickness at all ages, becoming statistically sig-
nificant at P6 (∗P , 0.05; two-way ANOVA with Bonferroni post hoc test). (C) Hippocampi from Nissl-stained brains at P1 and P6. (D) Bar chart showing total
hippocampal area in wild-type and Smn2/2;SMN2 mice at P1, P3 and P6. The hippocampal area in Smn2/2;SMN2 mice was smaller than in wild-type lit-
termates at all ages examined, but only became statistically significant at P6 (∗∗P , 0.01). (E) Bar chart showing the hippocampal dentate gyrus area in wild-type
and Smn2/2;SMN2 mice at P1, P3 and P6. The area of the dentate gyrus in Smn2/2;SMN2 mice was no different from that of wild-type littermates at P1 (ns
P . 0.05). However, by P6, the area of the dentate gyrus was 50% smaller in Smn2/2;SMN2 mice compared with wild-type littermates (∗∗∗P , 0.001). P1,
n ¼ 3 mice per genotype; P3, n ¼ 4; P6, n ¼ 3/4. Scale bar ¼ 160 mm.
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nuclei)—showed no difference in Smn2/2;SMN2 mice
(Fig. 5). Similarly, cell proliferation markers were not
altered in unaffected brain regions (Fig. 6).
To test whether the reduced cell density in the hippocampus
was occurring as a result of increased postnatal apoptotic cell
death, we compared caspase 3 expression in the hippocampus
of late-symptomatic Smn2/2;SMN2 and wild-type littermate
mice. Cells labelling positive for caspase 3 were found in very
low numbers in the hippocampus of both SMN2/2;SMN2
and wild-type littermate mice (Fig. 4E), and no significant
difference was observed between the genotypes (Fig. 4F;
P. 0.05, unpaired t-test). This suggested that reduced cell
densities were the result of abnormal proliferation rather
than a widespread loss of cells through activation of apoptotic
cell death pathways. Experiments comparing levels of
cell proliferation markers and apoptotic markers in
SMN2/2;SMN2 and wild-type littermate mice were also ana-
lysed as the ratio of the total number of cells present, with the
same results obtained as for those analysed using cells per unit
area (Fig. 6).
As the hippocampus is one of the few regions where neuro-
genesis can occur in the postnatal mammalian brain (16,17),
we next examined whether changes in expression levels of
established neurogenic markers were modified in the hippo-
campus of SMN2/2;SMN2 mice. Expression levels of the
neurogenesis marker doublecortin were quantified using fluor-
escent western blotting and revealed an 40% decrease in
SMN2/2;SMN2 mice compared with wild-type littermate
mice at P5 (Fig. 4G and H). We also observed an 25%
reduction in the expression levels of the neurogenesis
marker TUC-4 in the hippocampus of SMN2/2;SMN2
mice, although variability in the expression levels between
individual mice of both genotypes [consistent with previous
reports (18)] meant that this did not reach statistical signifi-
cance (data not shown). This finding suggests that postnatal
hippocampal neurogenesis was significantly impaired in
SMN2/2;SMN2 mice and was likely to contribute to the
reductions in cell density and proliferation previously
observed.
Modifications in morphology, cell density and proliferation
were most pronounced in brain regions with higher normal
expression levels of SMN protein
Quantitative analysis of basal SMN protein levels in brains from
wild-type mice confirmed higher expression levels in affected
regions such as the hippocampus compared with non-affected
regions such as thalamic VPM/VPL nuclei (Fig. 4I and J).
Figure 3. Morphological development occurs normally in the primary somatosensory cortex in severe SMA mice. (A) Photomicrographs showing representative
primary somatosensory cortices (S1BF; indicated by the white line in each micrograph) from Nissl-stained sections of brains from wild-type (WT; left panels)
and Smn2/2;SMN2 mice (right panels) at pre-symptomatic (P1) and late-symptomatic (P6) ages. No qualitative differences were observed in S1BF thickness
between genotypes at either age. (B) Bar chart (mean+SEM) showing average S1BF thickness in wild-type (+/+) and Smn2/2;SMN2 (2/2) mice at P1, P3
and P6. There was no significant difference observed between genotypes at any age examined (P . 0.05 for all comparisons; two-way ANOVA with Bonferroni
post hoc test. P1, n ¼ 3 mice; P3, n ¼ 4; P6, n ¼ 4/6). Scale bar ¼ 160 mm.
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Figure 4. Modified brain development in the hippocampus is associated with reduced cell density and cell proliferation, but not an increase in apoptosis. (A)
Confocal micrographs showing TOPRO3-labelled nuclei in the hippocampal dentate gyrus from wild-type (WT) and Smn2/2;SMN2 (SMA) mice at late-
symptomatic (P5) ages. (B) Bar chart (mean+SEM) showing cell density in the hippocampal dentate gyrus (granular layer) in wild-type (+/+) and
Smn2/2;SMN2 (2/2) mice at P5. There was a significant reduction in cell density in Smn2/2;SMN2 mice (∗∗P, 0.01; unpaired t-test). (C) Ki-67 immuno-
labelling (green; marking proliferating cells) and TOPRO3-labelled nuclei (blue) in the hippocampus from a wild-type mouse. (D) Bar chart showing Ki-67 cell
proliferation in the hippocampal dentate gyrus (granular layer) of wild-type and Smn2/2;SMN2 mice at P5. There was a significant reduction in the number of
Ki-67-positive cells in Smn2/2;SMN2 mice (∗∗∗P, 0.001; unpaired t-test). (E) Caspase-3 staining (green) and TOPRO3-labelled nuclei (blue) in the hippo-
campus from a P5 Smn2/2;SMN2 mouse. The high-power insets show examples of a cell positive for caspase-3 staining. (F) Bar chart showing no significant
difference in the numbers of caspase-3 positive cells between Smn2/2;SMN2 and wild-type littermate mice at P5 (ns P. 0.05; unpaired t-test). (G) Repre-
sentative fluorescent western blots showing reduced expression of the neurogenesis marker doublecortin (DCX) in Smn2/2;SMN2 mice (2/2). SMN levels are
also shown as are those of VDAC2 as a loading control. (H) Bar chart showing quantitative analysis of fluorescent western blots revealing significantly reduced
levels of DCX in the hippocampus from Smn2/2;SMN2 mice (2/2) compared with wild-type littermates (+/+) (∗P, 0.05, Mann–Whitney test). (I) Tri-
plicate fluorescent western blots showing expression levels of SMN and the VDAC2 loading control in the hippocampus (Hi) and thalamus (Th) of three wild-
type mice. (J) Bar chart showing quantitative analysis of fluorescent western blots revealing significantly higher levels of SMN in the hippocampus than in the
thalamus (∗P, 0.05, Mann–Whitney test). n ¼ 4 mice per genotype. Scale bar ¼ 35 mm (A and C) and 930 mm (E).
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These data are supported by previous reports of SMN transcript
levels in the mammalian brain, where particularly high
expression was noted in the hippocampus (12). Taken together,
this suggests that regions found to be most affected in the
brains of SMN2/2;SMN2 mice (e.g. the hippocampus) were
those normally associated with higher basal expression of SMN
in the healthy postnatal brain.
Proteomic analysis of the hippocampus in mice with severe
SMA reveals widespread modifications in expression levels
of proteins required for cellular proliferation, migration
and development
In an attempt to identify molecular correlates of the morpho-
logical and cellular changes observed in the brains of mice
with severe SMA, a quantitative proteomics analysis was
undertaken on isolated hippocampal tissues from
SMN2/2;SMN2 and wild-type littermate mice at a late-
symptomatic age (P5). Hippocampi from six
Smn2/2;SMN2 and six wild-type littermate mice were har-
vested for the analysis. Using a quantitative proteomics
approach (iTRAQ; see Materials and Methods for details),
219 347 individual peptide sequences were submitted to
MASCOT for identification. As an indication of identification
certainty, the false discovery rate for peptide matches above
the identity threshold was 2.06%. In order for inclusion and
further analysis, a protein had to be identified by at least
two peptides. In order to increase stringency in reporting, a
minimum cut-off of 20% change against wild-type littermates
was used.
A direct comparison of the hippocampal proteome from
Smn2/2;SMN2 and wild-type littermate mice revealed that
39 out of the 144 (27%) individual proteins identifiable
across all samples had modified expression levels .20% in
the hippocampus from Smn2/2;SMN2 mice (Table 1). Thir-
teen proteins had increased expression levels in
Smn2/2;SMN2 mice compared with wild-type littermates
and 26 proteins had reduced expression levels (Table 1).
Quantitative fluorescent western blotting was undertaken on
freshly prepared hippocampal tissues to validate the proteo-
mics data (Fig. 7A). Three individual proteins were selected
for validation because they showed a relatively large magni-
tude of change and because they were identified by low
numbers of unique peptides: isocitrate dehydrogenase (NAD)
subunit alpha (Idh3a) as a protein with increased expression
in the hippocampus of Smn2/2;SMN2 mice, and prothymo-
sin alpha (Ptma) and neural cell adhesion molecule 1
(Ncam1) as proteins with decreased expression. All three pro-
teins showed similar, significant changes in expression in the
hippocampus from Smn2/2;SMN2 mice when assessed
using western blotting, confirming the validity and reliability
of the proteomics data (Fig. 7B–D).
In order to confirm that the protein changes identified in the
hippocampus of Smn2/2;SMN2 mice were specific responses
to reduced SMN levels in affected tissues, we also quantified
expression levels of Ptma, Idh3a and Ncam1 in brain tissues
containing less affected regions as well as liver and skin (Sup-
plementary Material, Fig. S1). None of the proteins examined
showed changes in expression levels of a similar magnitude or
direction to those observed in the hippocampus.
Figure 5. No change in cell density or cell proliferation markers in the primary somatosensory cortex or unaffected thalamic nuclei in severe SMA mice. (A)
Representative confocal micrographs showing TOPRO3-labelled nuclei of all cells in the primary somatosensory cortex (S1BF) from wild-type (WT; left panel)
and Smn2/2;SMN2 (right panel) mice at late-symptomatic (P5) ages. No qualitative differences in cell density were observed in Smn2/2;SMN2 mice. (B) Bar
chart (mean+SEM) showing cell density measured in the S1BF region (layers IV and V) of the brain in wild-type (+/+) and Smn2/2;SMN2 (2/2) mice at
P5. There was no significant difference between the genotypes (ns P . 0.05; unpaired t-test. n ¼ 4 mice per genotype). (C) Representative confocal micrographs
showing TOPRO3-labelled nuclei of all cells in non-affected VPM/VPL thalamic nuclei from wild-type (left panel) and Smn2/2;SMN2 (right) mice at late-
symptomatic (P5) ages. No qualitative differences in cell density were observed in Smn2/2;SMN2 mice. (D) Bar chart showing cell density measured in the
thalamus in wild-type (+/+) and Smn2/2;SMN2 (2/2) mice at P5. There was no significant difference between the genotypes (ns P. 0.05; unpaired t-test;
n ¼ 4 mice per genotype). Scale bar ¼ 35 mm.
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Finally, to identify specific molecular pathways and net-
works disrupted in the hippocampus of Smn2/2;SMN2
mice, we undertook an in silico pathway analysis of our pro-
teomics data set using Ingenuity Pathway Analysis software.
This software incorporates information extracted by experts
from the full text of the scientific literature, allowing analysis
of candidate proteins with respect to their known roles in bio-
logical functions. This analysis revealed that many of the pro-
teins found to be modified in the hippocampus from
Smn2/2;SMN2 mice are involved in pathways related to
known genetic disorders including neurological, skeletal and
muscular disorders (Table 2). For example, 13 of our candi-
date proteins (representing 43.3% of our total candidate list)
have previously been shown to have a role in neurological dis-
orders. Importantly, many of the proteins modified in the hip-
pocampus in response to low SMN levels are known to be the
key regulators of cell proliferation, growth, migration and
morphological development (Table 2).
DISCUSSION
Data presented in the current study show for the first time that
high levels of SMN protein are required for normal brain
development in vivo. As a result, reduced expression of
SMN protein—down to levels sufficient to cause a severe
form of SMA in mice—caused abnormal brain development,
particularly affecting regions such as the hippocampus. We
have determined that reduced levels of cellular proliferation
and postnatal hippocampal neurogenesis, as well as modified
expression levels of proteins regulating proliferation,
migration and developmental processes, underlie these
abnormalities and are likely to contribute to disease pathogen-
esis in severe forms of SMA. The identification of downstream
molecular consequences of reduced SMN expression in the
brain also provides a significant opportunity to gain new
insights into the cell biology of the SMN protein and its
roles during development of the nervous system. Taken
together, these findings suggest that attempts to develop
novel therapeutic approaches for SMA will need to take into
account changes occurring in numerous regions of the
nervous system, including the brain, when considering treat-
ment targets and delivery options.
Our finding that low SMN levels disrupt cell proliferation
and neurogenesis in vivo provides the first direct evidence of
modified developmental processes in the brain during severe
forms of SMA. The observation that the hippocampus was par-
ticularly severely affected is in keeping with previous reports
showing high levels of SMN expression in hippocampal
neurons (12,19). It would now be of interest to examine
cell-type-specific responses in the hippocampus given pub-
lished data showing differential expression of SMN (19).
Our novel findings also provide indirect support to preliminary
reports suggesting that some lower motor neurons may be vul-
nerable in SMA due to aberrant developmental processes. For
example, microarray analysis of the spinal cord from mice
with a severe form of SMA has suggested that normal prolif-
erative pathways may be affected (11). Subsequent prelimi-
nary morphological investigations of proliferating cells in
the ventral horn of the spinal cord suggested that numbers
may be reduced in SMA mice (11). In addition, Simic and col-
leagues (20,21) have proposed a model whereby SMA patho-
genesis in lower motor neurons may occur via a combination
Figure 6. Reduced cell proliferation in the hippocampus of severe SMA mice was confirmed using a ratio analysis but no change in cell proliferation markers
was observed in unaffected thalamic nuclei. (A) Bar chart (mean+SEM) showing cell proliferation identified by Ki-67 staining in the hippocampus of wild-type
(+/+) and Smn2/2;SMN2 (2/2) mice at P5, analysed using a ratio analysis (ratio of Ki-67-positive cells to the total number of cells identified with TOPRO3
labelling; cf. with density analysis shown previously). There was a significant reduction in the number of Ki-67-positive cells analysed using both approaches in
the Smn2/2;SMN2 mice (∗∗P , 0.01; unpaired t-test. +/+ n ¼ 3 mice; 2/2 n ¼ 4 mice). (B and C) Bar charts showing cell proliferation identified by Ki-67
staining in the thalamus (VPM and VPL nuclei) of wild-type (+/+) and Smn2/2;SMN2 (2/2) mice at P5, analysed using both a density analysis (number of
cells per 10 000 mm2; B) and a ratio analysis (ratio of Ki-67-positive cells to the total number of cells identified with TOPRO3 labelling; C). In contrast to the
hippocampus, there was no reduction in the number of Ki-67-positive cells in the thalamus in Smn2/2;SMN2 mice (ns P . 0.05. +/+ n ¼ 3 mice; 2/2 n ¼ 4
mice). Scale bar ¼ 35 mm.
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of impaired axonogenesis, disrupted synapse formation and
abnormal motor neuron differentiation and migration.
Although recent studies have demonstrated that impaired axo-
nogenesis and disrupted synapse formation of lower motor
neuron processes are unlikely to be a major factor in SMA
pathogenesis in vivo (22), the finding that populations of
heterotopic lower motor neurons, which are migratory and dis-
placed, are dramatically increased in SMA spinal cord (20,21),
alongside data from the current study, suggest that pathways
regulating cellular proliferation and development may be
influencing pathogenesis in both motor and non-motor
regions of the nervous system. What remains unclear is
whether non-neuronal cells are affected alongside neuronal
cells in affected brain regions as well as in the spinal cord.
Table 1. Proteins with a change in expression levels .20% in the hippocampus of Smn2/2;SMN2 mice (KO) compared with littermate controls (WT)
Gene name Protein name Accession
number
Mol weight
(Da)
Average ratio
(KO/WT)+SD
Peptides
used/unique
Ion score
(Mascot)
P-value
Proteins upregulated in SMA mice
Idh3a Isoform 2 of isocitrate dehydrogenase
subunit a mitochondrial
IPI00608078.1 34 924 2.486+0.067 3/1 44 ,0.0001
Idh3a Isoform 1 of isocitrate dehydrogenase
subunit a mitochondrial
IPI00459725.2 43 816 2.486+0.067 3/1 44 ,0.0001
Atp5b Synthase subunit beta, mitochondrial ATP IPI00468481.2 59 724 1.475+0.374 21/4 277 ,0.0001
Try4 Trypsin 4 IPI00128108.1 28 382 1.437+0.080 8/1 114 ,0.0001
Pgam1 Phosphoglycerate mutase 1 IPI00457898.3 31 666 1.396+0.161 3/2 60 0.0065
Gm5803 Predicted gene 5803 IPI00947561.1 37 371 1.341+nn 4/1 53 nn
Tpm3 Isoform 2 of tropomyosin alpha-3 chain IPI00230044.5 32 689 1.335+0.185 3/1 51 0.0175
Mapt Microtubule-associated protein IPI00648564.1 47 178 1.258+nn 22/5 285 nn
Dbi Diazepam binding inhibitor isoform 1 IPI00222430.5 17 726 1.254+0.127 10/2 182 ,0.0001
Sod1 Superoxide dismutase IPI00458744.1 13 979 1.251+0.100 3/1 55 0.0061
Mapt Isoform Tau-C of microtubule-associated
protein tau
IPI00230408.2 40 793 1.247+nn 25/6 326 nn
Ywhah 14-3-3 protein eta IPI00227392.5 31 391 1.238+0.085 74/4 763 ,0.0001
Mtap2 Microtubule-associated protein 2 IPI00118075.1 221 307 1.237+nn 12/4 175 nn
Proteins downregulated in SMA mice
Ptma Prothymosin alpha IPI00224784.4 13 544 0.444+1.123 3/1 66 0.2197
Gm9034 Similar to glyceraldehyde-3-phosphate
dehydrogenase
IPI00753102.2 40 633 0.541+0.060 5/1 36 ,0.0001
Gm10290 Similar to glyceraldehyde-3-phosphate
dehydrogenase isoform 1
IPI00752289.2 40 199 0.617+0.099 20/2 236 ,0.0001
Cct2 T-complex protein 1 subunit beta IPI00320217.9 63 259 0.644+0.304 4/1 113 0.0288
Gm12141 similar to heat shock protein 1 IPI00749932.1 65 138 0.657+nn 4/1 131 nn
Rplp1 60S acidic ribosomal protein P1 IPI00113377.1 12 735 0.662+0.063 4/1 73 ,0.0001
Hspd1 Isoform 1 of 60 kDa heat shock protein,
mitochondrial
IPI00308885.6 69 014 0.667+0.161 15/2 454 ,0.0001
Aldoa Fructose-bisphosphate aldolase IPI00856379.1 49 583 0.674+nn 7/2 135 nn
Gm7293 Similar to glyceraldehyde-3-phosphate
dehydrogenase
IPI00751677.3 40 369 0.677+nn 7/3 50 nn
Gm14072 Hypothetical protein isoform 3 IPI00125787.4 18 543 0.692+0.282 2/1 42 n/a
Eif5a Eukaryotic translation initiation factor
5A-1
IPI00108125.4 19 067 0.693+0.231 11/2 128 ,0.0001
Gm3222 Similar to glyceraldehyde-3-phosphate
dehydrogenase
IPI00849879.1 44 463 0.694+nn 24/5 269 nn
Rps19 15 kDa protein IPI00857038.1 17 428 0.704+0.173 3/2 46 0.0207
Gm8683 Hypothetical protein IPI00875929.1 18 520 0.704+0.173 3/2 46 0.0207
Sncb Beta-synuclein IPI00131614.1 15 916 0.728+0.133 4/2 38 0.0032
H2afv 14 kDa protein IPI00555055.3 15 761 0.771+0.122 3/1 41 0.0156
Marcksl1 MARCKS-related protein IPI00281011.7 22 948 0.773+0.127 14/2 181 ,0.0001
Calm1 Calmodulin IPI00761696.2 18 124 0.774+0.143 20/4 167 ,0.0001
Ncam1 Isoform 1 of neural cell adhesion
molecule 1
IPI00122971.2 130 527 0.776+0.113 4/2 38 0.0037
Marcks Myristoylated alanine-rich C-kinase
substrate
IPI00229534.5 33 159 0.778+0.097 8/1 121 ,0.0001
Prdx2 16 kDa protein IPI00831115.3 17 619 0.78+0.105 22/4 177 ,0.0001
Arf4 ADP-ribosylation factor 4 IPI00331663.17 22 227 0.782+0.051 2/2 51 n/a
Gap43 Neuromodulin IPI00128973.1 28 200 0.789+0.157 28/3 361 ,0.0001
Nrgn Neurogranin IPI00380227.1 8728 0.795+0.123 8/1 126 0.0002
Rbm31y MCG53108 IPI00136573.1 66 759 0.796+0.068 14/1 128 ,0.0001
Tmsb4x Isoform short of thymosin beta-4 IPI00228757.1 6491 0.796+0.123 18/3 104 ,0.0001
P-values were calculated using an unpaired two-tailed t-test. nn, data not normally distributed so SD and P-value not available. n/a, P-value not calculated due to
n, 3 peptides.
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It will now be important to establish whether specific popu-
lations of cells (e.g. neurons, oligodendrocytes and/or micro-
glia) are particularly susceptible to the effects of low SMN
levels in the affected brain regions identified in this study.
The current study also adds a significant new dimension to
the hypothesis that low levels of SMN protein can have effects
on cells and tissues beyond the neuromuscular system. It has
previously been shown that SMA patients have an increased
incidence of congenital bone fractures, and mice with a
severe form of SMA are known to have decreased levels of
osteoblast differentiation markers (23). Similarly, the SMN
protein might be required for normal cardiogenesis, as
approximately three out of four patients with a single copy
of the SMN2 gene were shown to have haemodynamically rel-
evant atrial or ventricular septal defects (24), and SMN levels
have been reported to influence myoblast proliferation (25).
From a neurobiological perspective, previous reports have
demonstrated that populations of neurons outside the motor
system, notably sensory neurons in the periphery, are affected
when SMN levels are severely depleted in both humans and
mice (26,27). Taken together, these findings led to the gener-
ation of a ‘threshold’ hypothesis concerning the vulnerability
of different tissues and cells to pathological changes in
response to low SMN levels, where lower motor neurons are
the most sensitive cell type, but other cells and tissues sit
along a sliding scale of vulnerability. As the mouse model
employed in the current study recapitulates the physical and
genetic characteristics of a very severe form of SMA (equiv-
alent to type 0 or type I SMA in human patients), it is possible
that the pathological changes observed during brain develop-
ment have been revealed because the affected regions are
towards the vulnerable end of a resistance–vulnerability spec-
trum. As a result, it will now be of interest to establish whether
similar pathological changes can be observed, probably occur-
ring at lower levels (as patients with less severe forms of SMA
show no evidence of brain dysfunction or cognitive impair-
ment), in mouse models with a less severe form of the
disease [e.g. Smn+/2 mice (28)].
Finally, data presented here support sporadic reports in the
literature detailing low-level cytopathological changes in the
brain of human SMA patients (15,29–36), suggesting that
pathological changes in the nervous system of human patients
with the severest forms of SMA may extend beyond the neu-
romuscular system. Taken together, these findings suggest that
detailed neuropathological and/or neuroimaging studies on
human patients with the severest forms of SMA are now
required to accurately determine the long-term effects of low
SMN levels on human brain development. The likelihood of
undertaking such experiments on human post-mortem material
alone remains low because of a lack of available tissues result-
ing from genetic diagnosis rather than a diagnosis at autopsy.
Moreover, many of the currently available brain samples of
the SMA patient do not have the required associated level of
genetic information needed to accurately correlate pathologi-
cal changes with SMN expression levels (e.g. SMN1 mutation
analysis and SMN2 copy number). Detailed studies of human
SMA patients utilizing modern neuroimaging techniques are
therefore likely to be required.
Figure 7. Protein expression changes identified in the proteomics screen of SMA mouse hippocampus were validated using quantitative fluorescent western
blotting. (A) Representative fluorescent western blots showing expression levels of Idh3a, Ncam1 and Ptma in the hippocampus of Smn2/2;SMN2 (KO)
mice and wild-type littermates (WT) at P5. Smn protein levels are shown to confirm the genetic status of the Smn2/2;SMN2 mice and VDAC2 protein is
shown as a loading control. Note the increased level of expression of Idh3a in the Smn2/2;SMN2 mice, but decreased levels of both Ncam1 and Ptma, in
agreement with data from our proteomics experiments (Table 1). (B–D) Bar charts (mean+SEM) showing relative expression levels of Idh3a (B), Ncam1
(C) and Ptma (D) in wild-type (black bars) and Smn2/2;SMN2 (white bars) mice at P5. Note the significant increase in expression of Idh3a (∗∗P , 0.01;
Mann–Whitney test), and significant decrease in expression of both Ncam1 (∗∗∗P , 0.001) and Ptma (∗∗∗P , 0.001), in Smn2/2;SMN2 mice. n ¼ minimum
of three mice per genotype.
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Mice
Breeding pairs of Smn+/2;SMN2 mice (14) were originally
obtained from Jackson Laboratories. Breeding was carried
out under licence from the UK Home Office. Mice were
bred to produce litters that contained animals which were
wild-type (Smn+/+;SMN2), heterozygous for the SMN
mutation (Smn+/2;SMN2) and homozygous for the mutation
(Smn2/2;SMN2). Data were obtained from tissues harvested
from mice between postnatal Day 1 (P1; pre-symptomatic) and
P5/6 (late-symptomatic). A minimum of three mice per geno-
type were used in each experiment. Non-affected wild-type lit-
termate mice (Smn+/+;SMN2) were used as controls
throughout the study. Neonatal mice were sacrificed by
ice-bath chilling and decapitation, in accordance with the gui-
dance and rules of the UK Home Office. All mice were geno-
typed using standard PCR methods (14,37).
Tissue sections
Whole brains were removed from the exposed cranial cavity,
immediately collected into 4% paraformaldehyde solution
and fixed overnight before being transferred into 0.1 M PBS
and stored at 48C. Prior to histological sectioning, brains
were cryoprotected overnight in distilled water containing
30% sucrose at 48C. Each brain was weighed and photo-
graphed before being mounted on a freezing microtome in
OCT Embedding Matrix and cut coronally at a thickness of
48 mm for Nissl staining and 24 mm for immunohistochemical
staining. Nissl stain was realized using a standard protocol and
mounted in distyrene/plasticizer/xylene (DPX). For cell pro-
liferation analysis, coronal sections were immunohistochemi-
cally labelled with primary antibody (anti-Ki-67 polyclonal
antibody, 1:200, Abcam Cat No. 15580), secondary antibody
(FITC-conjugated Ig, 1:50, DAKO Cat No. F0205) and
co-stained with fluorescent nuclear dye (TOPRO-3, 1:100,
Invitrogen Molecular Probes Cat No. T3605). Only
Ki-67-positive cells directly corresponding to TOPRO-
labelled cell nuclei were included in cell proliferation
counts. For cell degeneration analysis, coronal sections were
immunohistochemically labelled with primary antibody (anti-
active Caspase-3 monoclonal antibody, 1:100 dilution, BD
Biosciences Cat No. 559565), secondary antibody (FITC-
conjugated Ig, 1:50) and co-stained with fluorescent nuclear
dye (TOPRO-3, 1:100).
Microscopy
Nissl-stained sections were imaged on an inverted bright-field
microscope (Olympus IX71S1F microscope) with a chilled
CCD camera (Hamamatsu C4742-95). Calibrated photomicro-
graphs (×4 magnification, ×1 binning) were collected using
Improvision Openlab software and imported into Image J for
morphological analysis. Immunostained sections were
mounted in Mowoilw (Calbiochem) and imaged on a laser
scanning confocal microscope (Zeiss LSM 510) using a ×63
magnification, oil-immersion lens (Plan-Apochromat 63×,
NA 1.4).
The precise depth of coronal brain sections selected for
morphological analyses was standardized using robust, easily
identifiable neuroanatomical landmarks illustrated in the
Paxinos Mouse Brain Atlas. All depth measurements are
described relative to Bregma. The decussation of the corpus cal-
losum (CC) at Bregma 1.10 mm and the obliquely oriented fas-
ciola corneum (FC) at Bregma 21.70 mm were employed as
neuroanatomical landmarks to identify sections containing the
primary motor cortex, hippocampal formation and primary
somatosensory cortex. The thickness of the primary motor
cortex was measured on three consecutive sections from
each side of the brain. In addition to the section in which the
CC first decussates, the sections immediately before and
Table 2. In silico functional pathways analysis of proteomics data shown in Table 1
Functional annotation Number of
proteins
% of candidate
list
Proteins
Genetic disorder 17 56.7 ALDOA, DBI, GAP43, HSPD1, MAPT, MARCKS, MARCKSL1, NCAM1, NRGN, PGAM1,
PRDX1, PRDX2, PTMA, RPS19, SNCB, SOD1, TMSB4X, TPM3
Neurological disorder 13 43.3 GAP43, HSPD1, MAPT, MARCKS, MARCKSL1, NCAM1, NRGN, PGAM1, PRDX1, PRDX2,
SNCB, SOD1, TMSB4X, TPM3
Cell death 13 43.3 ALDOA, CCT2, EIF5A, HSPD1, MAPT, NCAM1, NRGN, PRDX2, PTMA, SNCB, SOD1,
TMSB4X, TPM3
Skeletal and muscular
disorder
10 33.3 ALDOA, GAP43, MAPT, NRGN, PRDX2, PTMA, SNCB, SOD1, TMSB4X, TPM3
Proliferation of cells 9 30.0 EIF5A, HSPD1, MAPT, MARCKSL1, NCAM1, PRDX2, PTMA, RPS19, TPM3
Growth of cells 9 30.0 ATP5B, CALR, CCT2, EIF5A, GAP43, HNRNPD, HSPD1, MAPT, PTMA, SOD1, TMSB4X
Migration of cells 8 26.7 HSPD1, MAPT, MARCKS, NCAM1, PPIB, RPS19, TMSB4X, TPM3
Morphology of cells 7 23.3 GAP43, MAPT, MARCKS, MARCKSL1, PRDX2, TMSB4X, TPM3
Quantity of calcium 6 20.0 MARCKSL1, NCAM1, NRGN, PPIB, PRDX2, SOD1
Developmental disorder 6 20.0 GAP43, MAPT, MARCKS, MARCKSL1, SOD1, TPM3
Development of cells 6 20.0 GAP43, HSPD1, MARCKS, NCAM1, PRDX2, SOD1
Differentiation of cells 6 20.0 GAP43, HSPD1, MAPT, NCAM1, PRDX2, RPS19
Cell movement 6 20.0 HSPD1, MARCKS, RPS19, SOD1, TMSB4X, TPM3
Adhesion of cells 5 16.7 MARCKS, NCAM1, PPIB, PRDX2, TMSB4X
Outgrowth of neurites 5 16.7 GAP43, MAPT, MARCKS, NCAM1, TPM3
Transport of protein 4 13.3 ARF4, CALR, EIF5A, MAPT
Formation of filaments 4 13.3 GAP43, MAP1A, MAPT, TPM3
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after were also selected for measurement, approximating to
Bregma 1.15, 1.10 and 1.05 mm in the Paxinos Mouse Brain
Atlas. On each section, measurements were taken at three
equidistant points 250, 500 and 750 mm lateral to the angle of
the CC. The average of nine thickness measurements (three
measurements from three sections) taken on each side of the
brain was used to calculate the average thickness. A similar
approach was taken to measure the thickness of primary soma-
tosensory cortex, using the section in which the FC was first
observed in an oblique orientation, as well as sections immedi-
ately before and after, approximating to Bregma 21.65, 21.70
and 21.75 mm. On the same sections, the complete hippo-
campal area (excluding the fimbria) and the complete dentate
gyrus area were measured on each side of the brain. All
measurements were performed on randomized photomicro-
graphs using Image J software by a single researcher blinded
to specimen genotype.
Protein extraction and quantitative western blot analysis
Brains were rapidly removed and briefly chilled in ice-cold
ACSF (125 mM NaCl, 26 mM NaHCO3, 25 mM glucose,
2.5 mM KCl, 1.25 mM NaH2PO4, 1 mM CaCl2, 4 mM MgCl2)
before regions such as the VPM/VPL thalamic nuclei and hip-
pocampus were microdissected out. Quantitative fluorescent
western blotting was performed as previously described
(38–40). Membranes were incubated with primary antibodies
according to the manufacturer’s instructions [N-CAM1,
Sigma; SMN, doublecortin and PTa (N-18), Santa Cruz;
IDH3A, Lifespan Biosciences; VDAC2, b-actin and bIII-
tubulin, Abcam; TUC-4, Chemicon]. Odyssey secondary
antibodies were added according to the manufacturer’s
instructions (goat anti-rabbit IRDye 680 and goat anti-mouse
IRDye 800). Blots were imaged using an Odyssey Infrared
Imaging System (Li-COR Biosciences) at 169 mm resolution.
iTRAQ proteomics analysis
Protein was extracted in an MEBC buffer (50 mM Tris,
100 mM NaCl, 5 mM NaEDTA, 5 mM NaEGTA, 40 mM
b-glycerophosphate, 100 mM sodium fluoride (NaF), 100 mM
sodium orthovanadate, 0.25% NP-40, 1 Roche ‘complete’ pro-
tease inhibitor tablet, pH 7.4) before acetone precipitation and
labelling for iTRAQ analysis.
Hippocampal samples (n ¼ 6 mice per genotype) were pre-
cipitated with 2208C chilled acetone (1:4, v/v) and stored at
2208C overnight. The precipitates were spun at 48C for
10 min then washed with an acetone:water mixture (4:1,v/v)
twice prior to air-drying. The pellets were then resuspended
in an iTRAQ sample buffer [25 ml of 500 mM TEAB, 1 ml
of denaturant (2% SDS) and 2 ml of reducing agent
(TCEP)]. The samples were allowed to incubate for 1 h at
608C prior to protein estimation in triplicate (3 × 1 ml) by
microBCA assay (Pierce).
Aliquots of each sample equivalent to 100 mg were made up
to 28 ml using the iTRAQ sample buffer minus denaturant. To
each sample, 1 ml of 84 mM indole-3-acetic acid (IAA) was
added, and the samples were mixed and spun prior to incu-
bation at room temperature in the dark for 30 min. To each
sample, 10 ml of a 1 mg/ml solution of trypsin (sequencing
grade, Roche) in water was added and the samples incubated
overnight on a shaking platform at 308C. To each vial of
iTRAQ reagent, 70 ml of ethanol was added, mixed and
spun prior to transfer to each sample vial (WT-116,
SMA-114). The pH value was checked for each sample to
ensure pH was .8.0 prior to incubation for 1 h at room temp-
erature. One hundred microlitres of water were added to each
sample to quench the reaction prior to pooling of the two
iTRAQ-labelled samples and subsequent drying by vacuum
centrifugation.
The pooled iTRAQ sample was re-suspended in 25% aceto-
nitrile/0.1% formic acid (50 ml) prior to loading through a
home-made SCX ziptip using a 10% slurry of Poros HS
(10 ml) in a methanol:water mixture (50:50). The SCX
ziptip was equilibrated with 25% acetonitrile/0.1% formic
acid (3 × 25 ml) prior to loading of the pooled iTRAQ
sample. After sample loading, the SCX ziptip was washed
with 25% acetonitrile in 0.1% formic acid (3 × 25 ml). The
bound iTRAQ peptides were eluted from the SCX ziptip
using increasing millimolar concentrations of sodium chloride
(5, 10, 20, 50, 100,150, 200, 150, 300, 400, 800) in 25% aceto-
nitrile/0.1% formic acid (2 × 25 ml). A final elution of the
SCX ziptip with 200 mM NH4OH in 50% propanol was used
to remove most of the hydrophobic peptides. Each fraction
from the SCX ziptip was then dried by vacuum centrifugation
and stored until analysed by nano liquid chromatography-mass
spectrometry/mass spectrometry (nLC-MS/MS). Prior to the
analysis, each dried SCX fraction was re-suspended in 35 ml
of 1% formic acid and 10 ml aliquots were injected onto an
Agilent 6520 Q-TOF using an Agilent 1200 series nanoLC
system with microfluidic interface.
Raw data files were converted to mascot generic file (mgf) by
MassHunter workstation software prior to merging of the files
with Mascot Daemon and subsequent database (IPI Mouse)
searching with the Mascot search engine (Matrix Science,
Version 2.2). In keeping with recent recommendations for pub-
lication of proteomics data (41), full details of iTRAQ method-
ology can be found in Supplementary Methods.
Statistical analysis
All statistical analyses were completed using GraphPad Prism
software. P-values of ,0.05 were considered to be statisti-
cally significant for all analyses (∗P , 0.05; ∗∗P , 0.01;
∗∗∗P , 0.001).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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